Drug
Evobrutinib clinical trials
Also written MSC2364447C.
- studies test it
- 20
- open now
- 0
- in phase 3
- 4
- first study started
- 2015
How studies write it
Studies that test it under each name
Name
- M2951
- 15
Development codes
Studies by the year they started
20 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 4
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 0
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (11) · EMD Serono Research & Development Institute, Inc. (7) · Merck KGaA, Darmstadt, Germany (2)
Often tested with
Tested in the same studies.
Carbamazepine (1) · Digoxin (1) · Metformin (1) · Rosuvastatin (1) · Sumatriptan (1) · Midazolam (1)
Studies
Open first, then newest update. How each study uses evobrutinib is read from its arms, and is right about nine times in ten.
Testing it · 20
- DDI Study of Evobrutinib and CarbamazepineCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05248945Written as Evobrutinib
- Relative Bioavailability of Evobrutinib Tablet BatchesCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT07214922Written as Treatment A
- Drug-Drug Interaction Study of Evobrutinib and Transporter SubstratesCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05064488Written as Evobrutinib (45mg)
- A TQT Study of Effect of M2951 on Cardiac RepolarizationCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT07214935Written as M2951 Low Dose
- Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PKCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04546789Written as M2951 (BTK inhibitor)
- Study of Evobrutinib in Participants With RMS (evolutionRMS 1)TerminatedPhase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04338022Written as Evobrutinib
- A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple SclerosisTerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT02975349Written as Evobrutinib
- Study of Evobrutinib in Participants With RMS (evolutionRMS 2)TerminatedPhase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04338061Written as Evobrutinib
- Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05245396Written as Ref (TF2)
- Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)TerminatedPhase 3EMD Serono Research & Development Institute, Inc.NCT04032158Written as Evobrutinib
- Study of Evobrutinib in Participants With RMSTerminatedPhase 3EMD Serono Research & Development Institute, Inc.NCT04032171Written as Evobrutinib
- A Phase II Study of M2951 in SLETerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT02975336Written as M2951
- Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04697511Written as M2951
- Phase IIb Study of Evobrutinib in Subjects With Rheumatoid ArthritisCompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT03233230Written as M2591 25 mg QD
- Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial TabletsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04314024Written as Evobrutinib
- Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-EvobrutinibCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03725072Written as Evobrutinib
- Effect of Meal Composition and Timing on Evobrutinib BioavailabilityCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT03934502Written as Evobrutinib
- Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)CompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03436394Written as Evobrutinib
- Safety and Efficacy Study of M2951 in Participants With Rheumatoid ArthritisCompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT02784106Written as M2951
- MSC2364447C Phase 1b in Systemic Lupus ErythematosusCompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT02537028Written as MSC2364447C
Codes
What other systems call evobrutinib · ClinicalTrials.gg INT001117
- MeSH (NLM) C000632111evobrutinibOne source NLM
- UNII (FDA) ZA45457L1KEVOBRUTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27295200evobrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C141427EvobrutinibOne source FDA
- DrugBank DB15170One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632111 | evobrutinib | One source NLM |
| UNII (FDA) | ZA45457L1K | EVOBRUTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27295200 | evobrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C141427 | Evobrutinib | One source FDA |
| DrugBank | DB15170 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.